US7928093B2 - Amino-propanol derivatives - Google Patents

Amino-propanol derivatives Download PDF

Info

Publication number
US7928093B2
US7928093B2 US11/568,645 US56864505A US7928093B2 US 7928093 B2 US7928093 B2 US 7928093B2 US 56864505 A US56864505 A US 56864505A US 7928093 B2 US7928093 B2 US 7928093B2
Authority
US
United States
Prior art keywords
phenyl
formula
methyl
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US11/568,645
Other languages
English (en)
Other versions
US20070225260A1 (en
Inventor
Klaus Hinterding
Klemens Högenauer
Peter Nussbaumer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of US20070225260A1 publication Critical patent/US20070225260A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOGENAUER, KLEMENS, NUSSBAUMER, PETER, HINTERDING, KLAUS
Application granted granted Critical
Publication of US7928093B2 publication Critical patent/US7928093B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols

Definitions

  • the present invention relates to amino-propanol derivatives, process for their production, their uses and pharmaceutical compositions containing them.
  • Alkyl or alkyl moiety may be straight or branched chain, e.g. methyl, ethyl, propyl, iso-propyl or butyl.
  • Alkenyl may be e.g. vinyl.
  • Cycloalkyl may be e.g. C 3-6 cycloalkyl.
  • Acyl may be a residue W—CO wherein W is C 1-6 alkyl, C 3-6 cycloalkyl, phenyl or phenylC 1-4 alkyl.
  • Halogen may be F, Cl or Br, preferably F or Cl.
  • Heteroaryl may be a 5 to 8 membered aromatic ring comprising 1 to 4 heteroatoms selected from N, O and S, e.g. pyridyl, pyrimidinyl, pyrazinyl, furyl, oxazolyl, isoxazolyl, thienyl, thiazolyl, thiophenyl, isothiazolyl, pyrrolyl, imidazolyl, or pyrazolyl.
  • N, O and S e.g. pyridyl, pyrimidinyl, pyrazinyl, furyl, oxazolyl, isoxazolyl, thienyl, thiazolyl, thiophenyl, isothiazolyl, pyrrolyl, imidazolyl, or pyrazolyl.
  • heterocyclic residue is meant a 3 to 8, preferably 5 to 8, membered saturated or unsaturated heterocyclic ring comprising e.g. tetrahydrofuryl, tetrahydropyranyl, aziridinyl, piperidinyl, pyrrolidinyl, piperazinyl.
  • Compounds of formula I may exist in free form or in salt form, e.g. addition salts with e.g. inorganic acids, such as hydrochloride, hydrobromide or sulfate, salts with organic acids, such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate or benzenesulfonate salts.
  • inorganic acids such as hydrochloride, hydrobromide or sulfate
  • organic acids such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate or benzenesulfonate salts.
  • Compounds of formula I and their salts, in hydrate or solvate form are also part of the invention.
  • the compounds of formula I When the compounds of formula I have asymmetric centers in the molecule, various optical isomers are obtained.
  • the present invention also encompasses enantiomers, racemates, diastereoisomers and mixtures thereof.
  • the central carbon atom bearing R 1 , R 3 and NR 4 R 5 may have the R or S configuration.
  • Compounds having the following 3-dimensional configuration are generally preferred:
  • the present invention embraces cis-compounds, trans-compounds and mixtures thereof. Similar considerations apply in relation to starting materials exhibiting asymmetric carbon atoms or unsaturated bonds as mentioned above, e.g. compounds of formula II, or III as indicated below.
  • R 1 is CH 3 or CH 2 —OH
  • R 3 is a residue of formula —CH(R 8 )(OH) or of formula —CH(R 8 )(OPO(OR 9 )(OR 10 ))
  • each of R 4 and R 5 is hydrogen
  • X is O or a bond
  • R 7 is hydrogen, phenyl or thiophenyl
  • R 8 is methyl, ethyl, ethynyl or phenyl
  • R 9 is H
  • R 10 is H.
  • the present invention also includes a process for the preparation of a compound of formula I which process comprises
  • R 1 , R 2 and R 5 are as defined above
  • R′ 3 is —Y(R 8 )(OH) wherein Y and R 8 are as defined above
  • R 14 is an amino protecting group
  • R 1 , R 2 , R 14 and R 5 are as defined above, R′ 3 is a residue of formula (e′)
  • R′ 9 and R′ 10 are as defined above, and each of R′ 9 and R′ 10 , is a hydrolysable or hydrogenolysable group or R′ 9 and R′ 10 form together a divalent bridging residue optionally fused to a ring (e.g. benzene ring), and, where required, converting the compounds of formula I obtained in free form into the desired salt form, or vice versa.
  • a ring e.g. benzene ring
  • Removal of protecting group may be carried out in accordance with methods known in the art.
  • the removal of the amino protecting groups may conveniently be performed according to methods known in the art, e.g. by hydrolysis, e.g. in an acidic medium, for example using hydrochloric acid.
  • Examples of protecting groups for amino groups are e.g. as disclosed in “Protective Groups in Organic Synthesis” T. W. Greene, J. Wiley & Sons NY, 2 nd ed., chapter 7, 1991, and references therein, e.g.
  • benzyl p-methoxybenzyl, methoxymethyl, tetrahydro-pyranyl, trialkylsilyl, acyl, tert.-butoxy-carbonyl, benzyloxycarbonyl, 9-fluorenyl methoxy carbonyl, trifluoroacetyl, and the like.
  • the present invention also includes a process for the preparation of a compound of formula II, wherein X is O or S, which process comprises alkylating a compound of formula IV
  • R 1 , R 3 ′, R 4 ′, R 5 are as defined above, and R′ 2 is a radical of formula (a′) or (b′) or (c′) or (d′)
  • Alkylation of the compounds of formula IV may be performed according to methods known in the art, e.g. by nucleophilic substitution, e.g. by reaction with an alkylating agent R 6 —X 3 wherein X 3 is mesylate, tosylate, triflate, nosylate or an halogen, e.g. chloride, bromide or iodide.
  • the alkylation may also be carried out by following the Mitsunobu protocol (e.g. as disclosed in Hughes, Organic Preparations and Procedures International 28, 127-64, 1996 or D. L. Hughes, Org. React. 42, 335, 1992), in solution or on solid phase support synthesis, e.g. by attaching the compound of formula IV to a resin.
  • either triphenyl-phosphine or e.g. diethyl azocarboxylate bound to a resin, e.g. polystyrene can be used.
  • Methods A, B, G and H are known in the art, and may be performed e.g. as disclosed in K. Deutschending et al, Synthesis 2003, 1667.
  • M may be any metal or metal salt used in addition reactions to aldehydes known in the art, e.g. MgCl, MgBr, Mgl, Li, Zn, Cu.
  • PG means protecting group
  • reaction mixture is then poured onto a biphasic mixture of AcOEt and NaHCO 3 (saturated aqueous solution).
  • aqueous phase is extracted with AcOEt (3 times).
  • the combined organic layers are dried (Na 2 SO 4 ) and concentrated under reduced pressure.
  • Column chromatography eluting with 0% ⁇ 40% AcOEt in heptane gives ⁇ (R)-3-[4-(tert-Butyl-dimethyl-silanyloxy)-phenyl]-1-hydroxymethyl-1-methyl-propyl ⁇ -carbamic acid tert-butyl ester as a colourless oil.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound is purified by digeration with Et 2 O and is obtained as its hydrochloride salt.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 5 using appropriate starting materials.
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared analogously to Example 1 using appropriate starting materials.
  • the product is purified by RP-HPLC (ZORBAX Extend C-18) eluting with 5% ⁇ 95% CH 3 CN in H 2 O (+0.1% TFA).
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound is lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 9 using appropriate starting materials.
  • the product is purified by RP-HPLC (ZORBAX Extend C-18) eluting with 5% ⁇ 95% CH 3 CN in H 2 O (+0.1% TFA) to give the title compound.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound is lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound is lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 1 using appropriate starting materials.
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 18 using appropriate starting materials.
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the title compound is prepared as described in Example 18 using appropriate starting materials.
  • the compound was lyophilized from dioxane to give a white, amorphous powder.
  • the compounds of formula I in free form or in pharmaceutically acceptable salt form exhibit valuable pharmacological properties, e.g. lymphocyte recirculation modulating properties, e.g. as indicated in in vitro and in vivo tests and are therefore indicated for therapy.
  • useful pharmacological properties e.g. lymphocyte recirculation modulating properties, e.g. as indicated in in vitro and in vivo tests and are therefore indicated for therapy.
  • the compounds of formula I have binding affinity to individual human S1P receptors as determined in following assays:
  • S1P Sphingosine-1-phosphate
  • Agonist activities of compounds are tested on the human S1P receptors EDG-1 (S1P 1 ), EDG-3 (S1P 3 ), EDG-5 (S1P 2 ), EDG-6 (S1P 4 ) and EDG-8 (S1P 5 ).
  • Functional receptor activation is assessed by quantifying compound induced GTP [ ⁇ - 35 S] binding to membrane protein prepared from transfected CHO or RH7777 cells stably expressing the appropriate human S1P receptor.
  • the assay technology used is SPA (scintillation proximity based assay).
  • DMSO dissolved compounds are serially diluted and added to SPA-bead (Amersham-Pharmacia) immobilised SIP receptor expressing membrane protein (10-20 ⁇ g/well) in the presence of 50 mM Hepes, 100 mM NaCl, 10 mM MgCl 2 , 10 ⁇ M GDP, 0.1% fat free BSA and 0.2 nM GTP [ ⁇ - 35 S] (1200 Ci/mmol). After incubation in 96 well microtiterplates at RT for 120 min, unbound GTP [ ⁇ - 35 S] is separated by a centrifugation step. Luminescence of SPA beads triggered by membrane bound GTP [ ⁇ - 35 S] is quantified with a TOPcount plate reader (Packard). EC 50 s are calculated using standard curve fitting software. In this assay, the compounds of formula I have a binding affinity to S1P 1 receptor ⁇ 50 nM.
  • a compound of formula I or the vehicle is administered orally by gavage to rats.
  • Tail blood for hematological monitoring is obtained on day ⁇ 1 to give the baseline individual values, and at 2, 6, 24, 48 and 72 hours after application.
  • the compounds of formula I deplete peripheral blood lymphocytes when administered at a dose of 0.03 to 3 mg/kg. For example, following results are obtained: depletion of peripheral blood lymphocytes by more than 50%.
  • Example 1 0.07 mg/kg p.o. after 6 h
  • Example 12 0.4 mg/kg p.o. after 6 h
  • Example 13 0.5 mg/kg p.o. after 6 h
  • Example 14 0.1 mg/kg p.o. after 6 h
  • Example 15 0.6 mg/kg p.o. after 6 h
  • Example 17 0.2 mg/kg p.o. after 6 h
  • the compounds of formula I are, therefore, useful in the treatment and/or prevention of diseases or disorders mediated by lymphocytes interactions, e.g. in transplantation, such as acute or chronic rejection of cell, tissue or organ allo- or xenografts or delayed graft function, graft versus host disease, autoimmune diseases, e.g.
  • rheumatoid arthritis systemic lupus erythematosus, hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, psoriasis, Graves opthalmopathy, alopecia areata and others, allergic diseases, e.g. allergic asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, allergic contact dermatitis, inflammatory diseases optionally with underlying aberrant reactions, e.g.
  • inflammatory bowel disease Crohn's disease or ulcerative colitis
  • intrinsic asthma inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, atherosclerosis, osteoarthritis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, cutaneous manifestations of immunologically-mediated disorders, inflammatory eye disease, keratoconjunctivitis, myocarditis or hepatitis, ischemia/reperfusion injury, e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, traumatic shock, angiogenesis, Alzheimer's disease, cancer, e.g.
  • T cell lymphomas or T cell leukemias infectious diseases, e.g. toxic shock (e.g. superantigen induced), septic shock, adult respiratory distress syndrome or viral infections, e.g. AIDS, viral hepatitis, chronic bacterial infection, or senile dementia.
  • infectious diseases e.g. toxic shock (e.g. superantigen induced), septic shock, adult respiratory distress syndrome or viral infections, e.g. AIDS, viral hepatitis, chronic bacterial infection, or senile dementia.
  • cell, tissue or solid organ transplants include e.g. pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus.
  • the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired.
  • An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 100 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form.
  • Suitable unit dosage forms for oral administration comprise from ca. 0.1 to 50 mg active ingredient.
  • the compounds of formula I may be administered by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets or capsules, or parenterally, e.g. in the form of injectable solutions or suspensions, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form.
  • Pharmaceutical compositions comprising a compound of formula I in free form or in pharmaceutically acceptable salt form in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent.
  • the compounds of formula I wherein R 3 is a radical of formula (d), i.e. compounds of formula I.1, are administered perorally, and preferably have the R,R configuration as shown in FIG. 1.
  • the compounds of formula I wherein R 3 is a radical of formula (e), i.e. compounds of formula I.2 are administered parenterally, and preferably have the S,R configuration as shown in FIG. 1.
  • FIG. 1 Preferred Configuration of Compounds of Formula I.1 and I.2
  • the compounds of formula I may be administered in free form or in pharmaceutically acceptable salt form e.g. as indicated above.
  • Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
  • the present invention further provides:
  • the compounds of formula I may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of alio- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders, or a chemotherapeutic agent, e.g a malignant cell anti-proliferative agent.
  • the compounds of formula I may be used in combination with a calcineurin inhibitor, e.g. cyclosporin A, FK 506 or ISA TX 247; a mTOR inhibitor, e.g.
  • rapamycin 40-O-(2-hydroxyethyl)-rapamycin, CCI779, ABT578, AP23573, AP23464, AP23675, AP23841, TAFA-93, biolimus 7 or biolimus 9; an ascomycin having immunosuppressive properties, e.g. ABT-281, ASM981, etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic acid or a salt thereof, e.g.
  • immunosuppressive monoclonal antibodies e.g. monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40. CD45, CD58, CD80, CD86 or their ligands; other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g.
  • CTLA4Ig for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or a chemotherapeutic agent, e.g. paclitaxel, gemcitabine, cisplatinum, doxorubicin or 5-fluorouracil; or an anti-infectious agent.
  • adhesion molecule inhibitors e.g. LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists
  • a chemotherapeutic agent e.g. paclitaxel, gemcitabine, cisplatinum, doxorubicin or 5-fluorouracil
  • an anti-infectious agent e.g. paclitaxel, gemcitabine, cisplatinum, doxorubicin or 5-fluorouraci
  • the compounds of formula I are administered in conjunction with other immuno-suppressive/immunomodulatory, anti-inflammatory chemotherapeutic or anti-infectious therapy
  • dosages of the co-administered immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic or anti-infectious compound will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a calcineurin inhibitor, on the specific drug employed, on the condition being treated and so forth.
  • the present invention provides in a yet further aspect:
  • co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • pharmaceutical combination means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
  • fixed combination means that the active ingredients, e.g. a compound of formula I and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients, e.g. a compound of formula I and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient.
  • cocktail therapy e.g. the administration of 3 or more active ingredients.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US11/568,645 2004-05-27 2005-05-25 Amino-propanol derivatives Expired - Fee Related US7928093B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0411929.3A GB0411929D0 (en) 2004-05-27 2004-05-27 Organic compounds
GB0411929.3 2004-05-27
PCT/EP2005/005685 WO2005118523A1 (en) 2004-05-27 2005-05-25 Amino-propanol derivatives

Publications (2)

Publication Number Publication Date
US20070225260A1 US20070225260A1 (en) 2007-09-27
US7928093B2 true US7928093B2 (en) 2011-04-19

Family

ID=32671206

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/568,645 Expired - Fee Related US7928093B2 (en) 2004-05-27 2005-05-25 Amino-propanol derivatives

Country Status (17)

Country Link
US (1) US7928093B2 (zh)
EP (1) EP1753712B1 (zh)
JP (1) JP4490482B2 (zh)
KR (1) KR100837897B1 (zh)
CN (1) CN100575335C (zh)
AT (1) ATE431333T1 (zh)
AU (1) AU2005250112B2 (zh)
BR (1) BRPI0511610A (zh)
CA (1) CA2562332A1 (zh)
DE (1) DE602005014473D1 (zh)
ES (1) ES2327250T3 (zh)
GB (1) GB0411929D0 (zh)
MX (1) MXPA06013624A (zh)
PL (1) PL1753712T3 (zh)
PT (1) PT1753712E (zh)
RU (1) RU2006146215A (zh)
WO (1) WO2005118523A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004234067B2 (en) * 2003-04-30 2008-02-28 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法
EP1781595A1 (en) 2004-08-13 2007-05-09 Praecis Pharmaceuticals Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
US7795472B2 (en) * 2004-10-12 2010-09-14 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereof
MX2007006706A (es) 2004-12-06 2007-10-18 Univ Virginia Analogos de esfingosina 1-fosfato amida de arilo.
US8048928B2 (en) * 2005-10-07 2011-11-01 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease
RU2008134702A (ru) 2006-01-27 2010-03-10 Юниверсити Оф Вирждиния Пэтент Фаундейшн (Us) Способ лечения невропатической боли
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP1987013A1 (en) * 2006-02-09 2008-11-05 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
NZ574011A (en) * 2006-08-08 2011-10-28 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
SG174029A1 (en) 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
NZ576893A (en) 2006-11-21 2012-01-12 Univ Virginia Patent Found Tetralin analogs having sphingosine 1-phosphate agonist activity
CA2669124A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
EP2099741A2 (en) 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
AR074062A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0778263A1 (en) 1994-08-22 1997-06-11 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
WO2002076995A2 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
US20060211656A1 (en) * 2003-04-30 2006-09-21 Rainer Albert Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100551931B1 (ko) * 1997-04-04 2006-02-16 미츠비시 웰파마 가부시키가이샤 2-아미노프로판-1,3-디올 화합물, 이것의 의약으로서의 용도 및 합성 중간체
JP4166218B2 (ja) * 2002-09-13 2008-10-15 ノバルティス アクチエンゲゼルシャフト アミノ−プロパノール誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0778263A1 (en) 1994-08-22 1997-06-11 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
WO2002076995A2 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
US20060211656A1 (en) * 2003-04-30 2006-09-21 Rainer Albert Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hogenauer et al (ChemMedChem 3:1027-1029, 2008). *
Marins et al. J Lipid Res. Sterol side chain length and structure affect the clearance of chylomicron-like lipid emulsions in rats and mice. 39(2):302-312; 1998. *
Williams et al (Foye's Principles of Medicinal Chemistry, 5th Edition, pp. 50 and 59-61, 2002). *

Also Published As

Publication number Publication date
KR20070015439A (ko) 2007-02-02
PT1753712E (pt) 2009-08-06
PL1753712T3 (pl) 2009-10-30
DE602005014473D1 (en) 2009-06-25
AU2005250112A1 (en) 2005-12-15
JP4490482B2 (ja) 2010-06-23
JP2008500302A (ja) 2008-01-10
MXPA06013624A (es) 2007-02-28
ATE431333T1 (de) 2009-05-15
RU2006146215A (ru) 2008-07-10
US20070225260A1 (en) 2007-09-27
CA2562332A1 (en) 2005-12-15
WO2005118523A1 (en) 2005-12-15
BRPI0511610A (pt) 2008-01-02
ES2327250T3 (es) 2009-10-27
GB0411929D0 (en) 2004-06-30
CN1946679A (zh) 2007-04-11
CN100575335C (zh) 2009-12-30
KR100837897B1 (ko) 2008-06-13
AU2005250112B2 (en) 2009-01-08
EP1753712B1 (en) 2009-05-13
EP1753712A1 (en) 2007-02-21

Similar Documents

Publication Publication Date Title
US7928093B2 (en) Amino-propanol derivatives
US7728020B2 (en) Amino acid derivatives
JP4603531B2 (ja) スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体
US7326801B2 (en) 2-amino-propanol derivatives
US7825260B2 (en) Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
US7612238B2 (en) Amino-propanol derivatives
US7696184B2 (en) Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
KR100879831B1 (ko) 아미노산 유도체
MXPA06010284A (en) Amino acid derivatives
AU2002257719A1 (en) 2-amino-propanol derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HINTERDING, KLAUS;HOGENAUER, KLEMENS;NUSSBAUMER, PETER;REEL/FRAME:021940/0075;SIGNING DATES FROM 20061009 TO 20061011

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HINTERDING, KLAUS;HOGENAUER, KLEMENS;NUSSBAUMER, PETER;SIGNING DATES FROM 20061009 TO 20061011;REEL/FRAME:021940/0075

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20190419